Saint Medical was founded in April 2019 and has grown into an emerging force in the industry after 7 years of development.

Just a month ago, Saint Medical reached a milestone in its development —Xcor™ Transcatheter Aortic Valve Replacement System, independently developed by the team, has been officially approved for marketing by the National Medical Products Administration.

At that time, Ma Chenming, Chairman of Saint Medical, wrote in his WeChat Moments:"In Germany, a checkmark is written as 'X' – not a negation, but 'this is the one.' COR, from Latin, means 'heart.' Xcor™, born for the heart."

Ma Chenming is a typical high-level overseas returnee talent. He graduated from the Peking University Health Science Center, went to Germany for further studies in 2010, obtained his German medical license, and later worked at the Munich Heart Center – Germany's national cardiovascular disease center, which is best known for its minimally invasive heart surgeries.

During his time in Germany, Ma Zhenming was deeply moved to see many Chinese patients traveling thousands of miles to seek medical treatment in Germany – when will Chinese people be able to easily receive treatment for heart disease in China?

With this original intention, Ma Chenming gave up his job in Berlin in 2019,Coming to Nanjing to establish Saint Medical, determined to develop valve products suitable for the Chinese population.

Cardiac valves are a star sector in the medical industry, and aortic valves are the core area of competition within cardiac valves.

Currently,Aortic Valve StenosisA "hidden heart killer" that predominantly affects the elderly. As people age, the aortic valve gradually calcifies and narrows, impeding the heart's ability to pump blood. In severe cases, this can lead to heart failure, sudden death, and become life-threatening.

Transcatheter Aortic Valve Replacement (TAVR), as the core method of minimally invasive treatment,No need for open-heart surgery, valve replacement can be completed through minimally invasive intervention.Has long become the preferred treatment option for elderly and high-risk patients.

But in clinical practice, complex anatomical structures and postoperative complications have always been "stumbling blocks" troubling doctors and patients.

Saint Medical's Xcor™ targeted these pain points from the initial stage of development.

According to reports, the approval of Xcor™ has further enriched the product portfolio of TAVR devices made in China. Its innovative design for complex anatomical structures forms a differentiated complement to already approved products, markingChina has added another "locally produced alternative" product in the field of transcatheter aortic valve replacement that can rival international standards.

As of April 2026, the market for heart valve disease in China is in a stage of rapid development, particularly showing characteristics of high growth, high competition, and high innovation in the field of interventional treatment for structural heart disease.

Industry data shows that the市场规模 of TAVR in China was approximately 1.61 billion yuan in 2022 and is expected to reach 11.36 billion yuan by 2030, with a compound annual growth rate (CAGR) of 27.7%.

Currently, the global TAVR field is jointly constituted by international giants and emerging Chinese enterprises, with a competitive landscape characterized by "international dominance and the rise of Chinese production." This successful financing will help Saint Medical further explore niche areas and actively participate in market competition.